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Drugs used in Cardiological 
Practice
BY
BERTRAM A. BRADLOW,
M.I). (Rand.), m .k .c .p ., M.r .c .I’ . i:..
Phvsii  iun. Johannesburg .
It is manifestly impossible to deal with all the 
drugs used in cardiological practice. There are 
some 400 medical journals in tile English lan­
guage published annually, and these contain 
some 800 articles on cardiology, so that it is 
merely possible to touch on the fringe of the 
subject.1
The table (Table 1) shows the commoner 
drugs used in cardiology, and from this one 
can appreciate the enormous range.
TABLE 1
DIU'GS USED IN CARDIOLOGICAL PRACTICE
A. Cardiac Failure
1. Digitalis and similar cardiotonic drugs.
2. Diuretics: (a) Mercurials.
(h ) Cation exchange resins.
(c) Diamox.
(d) Theophyiene ethylene diamine, 
if) Ammonium chloride.
B. Arrhythmias
1. Digitalis and glycosides.
2. Ouabain (Strophanthin i .
3. Quinidine.
4. Procaine amide.
5. Procaine.
6. Potassium.
7. Mecholyl.
8. Prostigmine.
C, Vasodilators in Coronary I nsufficiency
1. Nitrates: Glyeeril trinitrin.
Metamine and praenitron.
2. Papaverine and paveril phosphate.
D. P eripheral Circulatory F ailure ( S hock i
(a) L. Nor-adrenaline (Levophed),
(h) Mephentermine (Wyaminei,
E. Hypertension 
Raurvolfia serpentina.
Hydralazine (Apresoline).
Methonium compounds (Vegolysen) 
Pentapyrollidum (Ansolysen).
Veratrine derivatives.
E. V n 111: i* * 11. - 
Rheumatic fever.
Suhacute haeterial I'lidocardiiis-
G. Antithyroid Agents to L ower Metabolic Needs
(a) Thiourae.il.
(b) Mereaptozole.
(c) Radio-active iodine.
II. \nti-Coagui.ants
(a) Heparin.
(1)) Dicounrarol.
I d  Phenylindanedione (Dindevan, Hedulin).
id i Tromexan.
Altention will be drawn to some of the newer 
drugs and to new facts concerning the older 
drugs such as digitalis, quinidine and the mer­
curial diuretics, which are still used very casually 
and w ithout due respect by most practitioners.
D ig it a l is
Digitalis is undoubtedly the most valuable 
drug used in cardiology. When, in 1775, 
Withering made use of what he thought was the 
diuretic property of the leaves of the foxglove, 
he could have had no idea of the impact of this 
drug on the future of medicine.
Digitalis is available in a varietv of forms, 
and it is important for the practitioner to become 
familiar with the use of two or three varieties 
at most, and to restrict himself to these particu­
lar drugs. The introduction of the purer glyco­
sides led to the belief that these substances were 
less toxic and more efficacious. However, it 
must be stressed that digitalis substances devoid 
of toxic properties are also therapeutically 
inert A” ft is necessary to have an idea of the 
equivalent doses of the various preparations. 
Table 2 is arranged to show the approximate
EQUIVALENT STRENGTHS 
(BY MOUTH)
POWDERED DIGITALIS LEAf (B.R) 
TINCTURE of DIGITALIS (B.R)
© DIGOXIN
© LANATOSIDE C (CED1LANID)
© DIGILANID
EfNATIVCLLCS DIGITAL1NE 
BlDIGITOXIN (e.g. PURODIGIN,
CRIST0DIGIN)
1 grain (65 mg.)
10 minims (0-6 ml.)
0 * 25 mg.
0 * 5 mg.
0 • 25 mg.
0 ‘ i  mg. (VfcoO grain) 
0 * 1 mg.
© GLYCOSIDES of DIGITALIS LANATA 
IB GLYCOSIDES of DIGITALIS PURPUREA
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equivalent in regard lo tablet size rather than 
lo give the exactly equivalent dosages.
The action of digitalis has been the subject 
of considerable study in recent years. The digi­
talis drugs are the only known substances which 
have a direct myocardial action and actually 
improve the vital function of the heart in pro­
pelling blood. They increase the force of systolic 
contraction of the heart with a consequent rise 
in cardiac output. By shortening the duration 
of systole they allow more time for ventricular 
filling and heart rest, with reduction of oxygen 
expenditure by the heart, and a digitalised heart 
can thus do the same or more work with less 
energy utilisation.
The second major cardiac action is on the 
heart rate. Two mechanisms slow the heart. 
Firstly, small doses of digitalis act on the sino- 
auricular and auriculc-ventricular nodes by vagal 
stimulation, and this effect can be abolished by 
atropine or exercise. Thus the patient with 
auricular fibrillation who has a satisfactory rate 
at rest but excessive tachycardia on exertion 
requires more digitalis. By increasing the dose 
the second mechanism arises. This is an in­
crease in the refractory period of muscle 
throughout the heart, especially' in the auriculo- 
ventricular node and bundle of His. The re­
sulting conduction defect accounts for the great 
value of digitalis in auricular fibrillation with 
rapid ventricular rate.
In the presence of failure with sinus rhythm, 
digitalis may improve the clinical state before 
there is a material reduction in heart rate, and 
subsequent slowing is often the result of restored 
compensation rather than the other way round.2" 
It is well known that in tachycardia without 
heart failure, as in thyrotoxicosis or fever, digi­
talis is ineffective in slowing the rate.
The extracardiac actions of digitalis are unim­
portant. While digoxin has been shown to have 
a moderate but definite diuretic action, even in 
non-cardiac oedema.2" diuresis in congestive 
failure is mainly secondary to improved cardiac 
function. Clinical improvement with digitalis 
often precedes any significant diuresis. Me- 
Michael4,5 at one time considered that digitalis 
acted by producing venoconstriction and lowered 
venous pressure with reduction of venous return 
and work load on the heart, but this has not 
been confirmed.4, 5
It is well to remember that digitalis has no 
effect on the contractile power of a normal myo­
cardium and does not increase the cardiac output 
in normal persons.23,5 Why digitalis acts on the 
failing myocardium is not known for certain,
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but suffice it to say that its action is dependent 
on cellular potassium, and that therapeutic doses 
increase while toxic doses decrease cellular 
potassium.21
There are four main indications for the use 
of digitalis. Firstly, nearly every case of con­
gestive failure requires digitalis. Some can be 
maintained on salt restriction and diuretics, but 
unless there is some special reason, digitalis 
should be used as a routine and may prove suffi­
cient by itself. It is of value in all phases of 
congestive failure from the incipient phase where 
the only symptom is effort dyspnoea, to ad­
vanced failure with raised venous pressure and 
dependent oedema, irrespective of whether the 
rhythm is regular or irregular. Secondly, the 
drug is indicated in auricular fibrillation or 
flutter with rapid ventricular rates even in the 
absence of failure. Thirdly, it is the agent of 
choice in cases of paroxysmal supraventricular 
tachycardia, when simpler measures of vagal 
stimulation such as carotid sinus pressure have 
proved unavailing. Finally, digitalis may be 
indicated as a therapeutic test when it is uncer­
tain whether dyspnoea is due to congestive 
failure or some respiratory disease such as 
emphysema.
Congestive failure does not always respond to 
digitalis. In thyrotoxicosis, emphysema, anaemia 
and other “high output” failures there may be 
little or no improvement, and failure due to 
mechanical causes such as constrictive pericar­
ditis or pericardial effusion may not respond 
unless in addition the myocardium is itself 
diseased. Digitalis is often said to- be of little 
value in failure due to acute rheumatic carditis, 
hut this is probably untrue.12
There are practically no contraindications to 
the use of digitalis, but it should he used with 
care in certain conditions. Tn heart block, digi­
talisation should he slow and the onset of a 
Stokes-Adam attack would indicate the need to 
stop the drug. Tn the first few days after a 
myocardial infarction it is possible that digitalis 
may precipitate ventricular fibrillation.6 and if 
it is necessary to use it for failure, quinidine 
should be used simultaneously. Digitalis is best 
avoided in paroxysmal ventricular tachycardia 
in order to avoid the danger of ventricular 
fibrillation.
Digitalis intoxication is common and is due 
to the very narrow margin between the toxic 
dose and digitalising dose.7 With most prepa­
rations about 60 per cent, of the toxic dose is 
necessary to produce a therapeutic effect, but 
this margin may be greater with one of the
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newer glycosides called Gitalin.-' Phis fuel 
makes it essential to he familiar with the signs 
of toxicity.
Allergic idiosyncrasy or hypersensitivity rarely 
if ever occurs and may he discounted.
It is important to realise that the extent of 
failure, serum electrolyte levels and the use of 
other drugs such as diuretics all have some hear­
ing on the onset of toxicity. As a rule too the 
more severe the myocardial disease and the 
older the patient, the less is the margin between 
the toxic and therapeutic effects.7
The earliest toxic effects are related to the 
gastro-intestinal tract. Anorexia, and later 
nausea, vomiting and diarrhoea, are the most 
frequent symptoms of overdosage.2"’ 7 The\ 
occur whether the drug is administered orallv 
or parenterally. and are mainly of central origin. 
Nausea after the first dose or two is due to 
gastric irritation, and is less likely to occur with 
the purer glycosides, especially digitoxin. but
after initial digitalisation anorexia or nausea 
indicate overdosage.
Central nervous system symptoms are usually 
early and should be enquired after in cases of 
nausea where the question of toxicity is in doubt. 
A change in personality in a cheerful individual 
to a morose, melancholy person is common. 
Headache is frequent and may be the sole sub­
jective symptom of toxicity, while in elderly 
patients nocturnal restlessness, lassitude, apathy, 
delirium and confusion may occur. Vertigo is 
unusual, hut may be severe enough to make an 
ambulatory patient bedridden. Direct question­
ing reveals that, blurred or yellow vision or "dots 
before the eyes” occur in 25 per cent, of 
patients.23
As most of these effects may also be caused 
bv cardiac failure or anoxia, they may he over­
looked as signs of toxicity and increased doses 
of digitalis may actually be given!
Unfortunately too the more serious sign> of
'AL1S E ffE C T  on ELECTROCARDIOGRAM
yDIGITALIS N ote  shorh Q T In tervo l.
11
■4
Hmyogardial isc h aem ia
Q T Normal or Proionq ue.d
Fig. 1 ,. , ,
(Modified from Goldberger (1953) Unipolar Lead Electrocardiography H. Kempton. London, l
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toxicity such as arrhythmias may occur without 
any of the above subjective symptoms.
The most important toxic effects are the car­
diac disturbances, and virtually every form of 
arrhythmia and conduction disturbance has been 
attributed to digitalis. The earliest change is 
in the electrocardiogram. Figures 1 and 2
show the “scooped” ST segment with inversion 
of the first portion of the T  wave and the 
shortened QT interval. These changes provide 
no index of the therapeutic activity of the drug, 
nor do they indicate the presence of toxicity, 
and severe digitalis poisoning may occur in their 
absence.2"
Apart from gastro-intestinal symptoms, ven­
tricular extra-systoles are the most common 
indication of overdosage and indicate that 50 to 
80 per cent, of a lethal dose has been given. A 
bigeminal rhythm in which every alternate beat 
is due to a ventricular extra-syrslole is a further 
stage of toxicity and may be felt at the wrist. 
Unidirectional or bidirectional paroxysmal ven­
tricular tachycardia as seen on the electrocardio­
gram may follow, and at this stage fatal
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ventricular fibrillation is imminent. Various 
degrees of heart block may also occur. Unfor­
tunately these arrhythmias may only occur 
sporadically on straining at stool, or with anoxia 
or exertion, and may remain unnoticed. It is 
of interest that in normal individuals these 
arrhythmias seldom result from an overdose of 
digitalis. Toxicity may persist for days and 
sometimes even months after the drug has been 
stopped, especiallv in the presence of electrolyte 
disturbances.
An often forgotten danger in tile digitalised 
patient is the use of intravenous calcium which, 
because of its synergistic action with digitalis, 
may cause sudden death.
It is now' known that a profound relationship 
exists between digitalis and the body potassium, 
and that toxic doses liberate potassium from 
heart muscle, while therapeutic doses restore the 
cellular potassium.2" In congestive failure there 
is a loss of body potassium. This loss is aggra­
vated by such factors as mercurial diuretics and 
low salt diets, which also accentuate an electro­
lyte shift between intracellular and extracellular
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compartments so tliat cellular potassium i.-, de­
pleted while the serum potassium remains 
normal.21* The potassium loss lowers the body's 
threshold to the toxic action of digitalis, and 
explains the well known phenomenon of ‘"posl- 
mercurial redigitalisation. It is well recognised 
that for 24 to 48 hours after an injection of a 
mercurial diuretic, a digitalised patient may 
experience nausea and other signs of digitalis 
overdosage. This is now thought to be due to 
the production of a negative potassium balance 
despite a normal serum potassium, and can he 
prevented by oral administration of potassium.
A curious side effect of long continued digitalis 
is the production of gynecomastia in men. due 
to its oestrogen-like structure. Digitalis has 
also been said to cause intravascular thrombosis, 
hut this is open to considerable doubt and is 
only a very academic objection to its use.1’-9
The treatment of digitalis intoxication consists 
of withdrawing digitalis when in doubt, restrict­
ing the patient’s activities and withholding mer­
curial diuretics, doca or cortisone which cause 
potassium loss. Potassium chloride in doses of 
3-5 gm. per day in divided doses should be 
administered. For severe intoxication 5 gm. 
can be given in one dose in iced orange juice.21.
Procaine amide fPronestyd) can also be used 
in the treatment of digitalis-produced arrhyth­
mias and will be discussed later.
With any preparation of digitalis, digitalisa­
tion should if possible be achieved gradually, 
starting with a large dose, and giving pro­
gressively smaller doses, so that the possible 
appearance of toxic signs is not aggravated by 
further large doses. The oral route is suitable 
for at least 95 per cent, of cases and is always 
to be preferred to the intravenous route. With 
digitoxin, "single dose digitalisation’’ is possible, 
as this substance is not irritant to the gastric 
mucosa and is completed absorbed.1'1 While 
1.2 mg. of digitoxin is sulli- 
cient for most patients, it is 
toxic for a few and inadequate 
for others and this method is 
not to be recommended. Gas­
tric irritation prohibits the 
use of such large single doses 
with digitalis leaf or digoxin. 
and a digitalising dose can be 
spread over 24 hours or more 
with the avoidance of toxicity.
The table (Table 3) shows the 
usual oral digitalising doses of 
the common preparations.
Intravenous digitalisation should be reserved 
for the few patients unable to take oral medica­
tion because of coma or vomiting due to other 
causes, or for cases of pulmonary oedema and 
some cases of supraventricular tachycardia or
PREPARATION
ORAL
DIGITALIZING
DOSE
DAILY
MAINTENANCE
DOSE
DIGITALIS LEAF 9gr. 6gr. 3gr. 
ah 6- hourly intervals 
fo fotal of £ 2.2 grains
1-3  groins
DIGOXIN V i mg. followed by Img. 
and 0-£mg. 6- hourly 
fo fofal of Z - 5 mg.
0-25 - 075 mg.
DIGITOXIN 1*2 -2 mg. in single 
or divided doses
01 -  0*3 mg.
TABLE 3
auricular fibrillation. If possible thG route 
should be avoided in patients who have had 
digitalis within the preceding six weeks, and if 
used the drug should be injected in very' small 
doses with intervals of an hour or more to see 
the effect before repeating the dose. Once the 
patient can take the drug by mouth, intravenous 
administration should cease. Table 4  shows the 
usual intravenous digitalising doses and their 
times of action.
Once a digitalising dose has been given, a 
maintenance dose is prescribed. Tn the presence 
of auricular fibrillation an adequate dose is one 
which keeps the apical and pulse rates at ap­
proximately 70 per minute and which does not 
produce toxicity or allow too much acceleration 
on effort. In the presence of regular rhythm.
INTRAVENOUS DIGITALIZATION
PREPARATION DOSE ONSET oP ACTION PEAK of ACTION DURATION
CEDI L A N  ID t > 8  -  1 2  mg. 
( 4  - b c c . )
2 0  -  3 0  m in u tes 2 - 4  hours 2 4 - 4 8  hours
D IG O X IN
(D ilu te  w ith  9  vc
1 0  -  1 5  mg. 
s. o f  S a l in e )
2 0  -  5 0  m ins. 2  “  4  hours 2 4 - 4 8  hours
/O U A B A IN
IS TR O P N A N TU IN
0  2 5  -  0 -75  mg 5 - 2 0  m ins. 1 -  2  hours 1 2 - 2 4  ho u rs
TABLE 4
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if clinical benefit is not apparent, it may be 
necessary to push the dose to toxic levels pro­
ducing mild gastro-intestinal symptoms, and then 
withholding the drug for 18-72 hours, in order 
to know that the initial dose has been adequate.11 
If using digitoxin it must he borne in mind that 
the excretion is very slow and, particularly in 
elderly people, is liable to produce cumulative 
effects with severe intoxication. The use of 
digitoxin is partially responsible for the increas­
ing incidence of digitalis intoxication.-' Table 
1 shows the usual maintenance do.-es. but each 
patient is an individual problem.
Drt iu :t i c s
1’he mercurial diuretics are so well known as 
to require little in the way of description. All 
known makes contain 4-0 mg. of mercury in 
various organic forms per millilitre, and all 
except Thiomerin are chemically linked with
theophylline.11 They are very safe drugs when 
one considers the enormous number of mercurial 
diuretics given daily and the really insignificant 
number of toxic reactions and fatalities. It is 
probable that they act mainly by preventing 
renal tubular reabsorption of chlorides with re­
sultant excretion of sodium and water. Mer­
curial diuretics are indicated in congestive 
failure not responding adequately to full digi­
talisation. acute pulmonary oedema and some 
cases of angina decubitus or nocturnal dyspnoea. 
In themselves they are not adequate treatment 
for cardiac failure.11 and are really supplementary 
to the use of digitalis. The only real contra­
indication to their use in heart failure is known 
severe impairment of renal function. Albu­
minuria and a moderalelv raised blood urea are 
almost invariable accompaniments of congestive 
failure and should he disregarded. A real 
contraindication to further mercurials is lack
Fi-o .i This shows the weight loss and diuresis prnduced in conuestir e failure liy a 
mercurial diuretic.
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of response lo two or three injections, as in 
these cases mercurialism may result. Intraven­
ous administration, although more effective, is 
seldom advisable, as the intramuscular route is 
safer.11- Mercurials should be administered in 
(he morning so thaL the patient is not disturbed 
during the night by the diuretic effect.
An effective response is the loss of A lbs. body 
weight in 24 hours. Daily weighing provides a 
good indication of when (he next injection i- 
due, a gain of 3 lbs. or more suggesting the 
need for a further injection. The usual dose is 
1-2 ml. on alternate days, but if necessary in­
jections can be given daily or at weekly or 
forlnightlv intervals, depending on the response. 
Figure 3 shows the amount of weight loss in­
duced in congestive failure by a mercurial 
diuretic.
It is important to remember that frequent and 
prolonged use of mercurial diuretics cause a 
negative potassium balance, and potassium should 
be supplied in the form of a glass of fresh 
orange juice daily.
Thiomerin differs from other mercurial 
diuretics in that (he organic mercury is combined 
with mercaptan. Mercaptan abolishes the toxic 
effects of mercury, and as the injection is rela­
tively painless it can be given by subcutaneous 
injection. It is extremely effective by this route, 
and as it is so non-toxic can be safely adminis­
tered by the patient himself without fear of 
mercurialism. Figure 4 shows how an intelligent 
patient can control his own weight and symptoms.
Another new preparation is an allylurea 
mercurial compound intended for oral use and
Iki.
ISO
M.E. AGE39YRS. MALE M.[. t M.S.tTI. (DIGITALISED PATIENT)
WEIGHT IN LBS. RECORDED BEFORE AND 24 HOURS AFTER INJECTIONS!
147
14?
144
WEIGHTS
NOT
A C C O R D E D
144. 145 A
/
1ST
/
159
145
158
145
138
145,1 Ti
139
140
145,///
142
145
/
140'
147//
___ r_
/
140'
t  x  1  l l l l iII I 11!1  JL J 1* i—i }  5
T4JI0MERIN INJECTIONS!im f  I I I I I ■ T l - I T T
22 MAY 27* 3 JUNE 10* 17* 2 f  24* 2JULY 4T If"  17" 24
Fig. 4—The effect of self-administered Thiomerin injections on body weight in congestive 
cardiac failure.
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known as chlormerodrin. which is available under 
the trade name of iNeohydrin. This substance 
is unique among mercurial diuretics because its 
potency by mouth is actually as high as one- 
fourth of its potency by intramuscular injection, 
and a dose of C-<> tablets daily achieves the 
same effect as 2 cc. of mercuhydrjn by injection 
twice weekly. On this dosage at least 25 to 50 
per cent, of patients develop nausea, vomiting, 
diarrhoea, abdominal cramps and melaena.17 
However, smaller doses such as 1 or 2 tablets 
daily may be effective in reducing the frequency 
of injections without producing these symptoms. 
The tablets are lies! administered after food and 
it is wise to increase the dose slowly over a 
period of days in order to prevent gastrointes­
tinal upsets. It is possible that if the total daily 
dose is given in a single dose after breakfast, 
it is more effective than in divided doses. In 
the patients who can tolerate it. it is a most 
effective agent.
Lnfortunalely mercurial diuretics are not free 
of danger. Rare cases of hypersensitivity with 
rigors, pyrexia, chest pain, skin rashes and even 
sudden death have been reported. Mercurial ism 
may occur in patients with poor renal function 
and inadequate diuretic response. Rapid diuresis 
and dehydration may cause an increased clotting 
tendency and intravascular thrombosis.19
When the effect of a mercurial diuretic is 
inadequate, several substances may he used to 
enhance the effecL. Of these, ammonium 
chloride in doses of 15 gr. three times daily for 
two to four days preceding injection is the most 
effective and prevents excessive chloride loss. 
The slow intravenous injection of gr. amino- 
phylline two hours after a mercurial injection 
is an excellent potentiator because it increases 
the glomerular filtration rate.1’2 Intravenous 
ascorbic acid, magnesium sulphate, dehydro- 
cholin and pyridoxine are also said to act as 
potentiators.1"' 2U 23
When no response is obtained with a mercurial 
diuretic, there may be several causes. Firstly, 
physical exertion within 12 hours after adminis­
tration mav stop the diuretic effect.11 Secondly, 
the concomitant administration of opiates, bar­
biturates or pethidine may diminish, delay or 
even prevent, diuresis. The third and most 
important cause of mercurial resistance is dis­
turbance in electrolyte balance.22 The import­
ance of this cannot he over-emphasised. Chloride 
loss may cause hypochloraemie alkalosis as 
shown by a very low serum chloride value.
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This condition can he prevented by the ad­
ministration of ammonium chloride, which 
should, however, only be given for two to four 
days at a time, as overdosage of this drug may 
in itself cause stupor or coma and mercurial 
resistance due to acidosis.11 The use of a low 
sodium diet with mercurials may result in the 
low salt syndrome, especially in warm weather. 
This syndrome is characterised by anorexia, 
weakness, muscle cramps and mercurial resist­
ance. The serum sodium is low and the blood 
urea is raised. The ingestion of salt or intra­
venous infusion of small amounts of hypertonic 
solutions of sodium chloride may restore mer­
curial responsiveness. Finally, the fact that 
mercurials increase potassium lo.-s and thus 
cause electrolyte "shifts’’ has already been men­
tioned.
Recently we have seen the introduction of a 
new oral diuretic named Diamox. This sub­
stance is a sulphonamide derivative and inhibits 
the action of the enzyme carbonic anyhdrase. 
This enzyme is responsible for the formation 
of carbonic acid from carbon dioxide and water 
in the renal tubule as shown in Figure 5. The 
carbonic acid breaks down normally into a
■ACTION of CARBONIC ANWYDRASC 
in RENAL TUBULES
CARBONIC ANHYDRASE
-H2O + C O z -  ■ ^ ■H2CO3
h>co3 ------W+WCO3"
I I
EXCRETED REABSORBED 
in URINE info BLOOD
Fig. 5.
hydrogen ion which is excreted in the urine, 
causing urinary acidification, and bicarbonate 
which is reabsorbed into the blood. This 
reaction is prevented by Diamox, and as a result 
the bicarbonate is excreted, taking with it first 
potassium and later sodium ions and thus pro­
ducing a diuresis.21 A mild hyperchloraemic 
acidosis occurs in the scrum. In summary, the 
effect is on the serum bicarbonate, and when 
this has been lowered sufficiently to produce mild 
acidosis, the drug ceases to act. However, in 
cases of respiratory alkalosis with a high serum
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bicarbonate such as cor pulmonale, a heller 
theoretical response may be expected. Diamox 
is best administered in llie early morning in a 
single dose of 5 mg. per kilogram of body weight. 
This usually means a dose of one to one and a 
half 250 mg. tablets daily. No side effects June 
been reported aparl from dron.-im-s.- and para- 
esthesias of the fingers with daily doses of over 
500 mg., but as a maximum response occur.- 
with a smaller dose, such large dosage is un­
necessary.-’ In niv experience its diurelie 
properties are mild, figure 0 shows a typical 
average response. In approximately 50 per cent, 
of cases the weight loss from the daily dose i- 
under one pound.-3 Like ammonium chloride, 
however, it enhances the effects of mercurial 
diuretics, but cannot be used together with 
ammonium chloride, as they both tend to cause 
hyperchloraemic acidosis. It should only he 
given intermittently for three to live days at a 
time, us patients soon become unresponsive.
While it is not proposed to discuss the cation- 
exchange resins, their value in certain cases of 
chronic heart failure with no renal impairment 
should he remembered.2"--’
Attain TttxiiAS
Of the drugs used for arrhythmia.-, quinidine 
is the most, important. It is a drug which is too 
often feared or incorrectly used. Its onlv value 
is to stop or prevent ectopic cardiac arrhythmias.
Among its important actions is the possibility 
of increasing the ventricular rate by vagal block. 
The auricular rate is. however, slowed and the 
excitability of heart muscle is depressed.2"
It is often said to he a myocardial poison and 
to reduce the contractile force of the heart, hut 
in therapeutic doses this effect is negligible.2" A 
significant fall in blood pressure is rare with 
oral therapy, but may occur with rapid intra­
venous injection.2"
M r I L -Aged 48 yn. HYPERTENSIVE C.C-F. ( DIG1TALIS£D PATIENT)
AU G . 1954 11*" 12* 13* 14*" 15* 16* 17*NORN EVE HORN EVE MORN EVE NORN EVE. MORN. EVE MORN EVE MORN EVE
! I ’ 1- I i~ ‘- t  I I
1 1 1  r  1 NIL NIL
Fi^. 6- This shows the typical diuretic response to Diamox
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Cinclionism in the form of tinnitus, blurred 
vision, urticaria and nausea may occur and 
should always be tested for with a preliminary 
dose of 3 gr. before proceeding to use therapeutic: 
doses.
The danger of pulmonary embolism due to 
quinidine in reverting long standing cases of 
auricular fibrillation to sinus rhythm has prob­
ably been over-stressed in the past, and emboli 
are commoner in patients with established 
fibrillation than in cases of reversion.29 How­
ever, in patients with a history of recurrent 
embolisation it is wiser to use anticoagulants 
for two weeks before using quinidine.3" Sudden 
death due to ventricular standstill or ventricular 
fibrillation has been reported, but must be very 
rare.31 Kven considering these dangers, quini­
dine is a reasonably safe drug if properly used. 
In auricular fibrillation or flutter it is advisable 
to digitalise the patient before using quinidine. 
which may cause a dangerous increase in ven­
tricular rate if used alone; and when using doses 
in the neighbourhood of 45 gr. or more daily, 
frequent electrocardiograms are advisable. An 
increase of 50 per cent, in the width of the QRS 
interval over the pre-treatment measurement is 
an indication to slop quinidine therapy.28-3"-31
Quinidine therapy is of no value unless the 
arrhythmia is either slopped or prevented. A 
small maintenance dose of quinidine in cases of 
recurrent paroxysmal tachycardia is useless un­
less it is sufficient to prevent further attacks.
A common dosage schedule is to give 6 gr. 
of quinidine sulphate every two hours for five 
doses to stop an arrhythmia. If  unsuccessful, 
9 gr. every two hours for five doses can be given 
over the next two days. Bigger doses require 
electrocardiographic control. Phenobarbitone 
l l  grain ) one hour before the first dose and 
amphogel with each dose help to prevent nausea.
For prophylaxis of arrhythmias or ectopic- 
beats. 6 gr. four times daily are usually neces­
sary and can be continued indefinitely without 
harm.31 Smaller or larger doses may be neces­
sary in individual patients.
Should parenteral quinidine be necessary, it 
is probably better to use Pronestyl I procaine 
amide). This drug has essentially the same 
physiological effects and dangers as quinidine. 
but does not cause cinchonism and is much less 
effective than quinidine in the treatment of 
supraventricular tachycardia. Prolonged oral 
use has been known to cause agranulocytosis.32 
Unlike procaine, it is stable in the body and in
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therapeutic doses has no eonvulsanl action. It 
is completely absorbed from the gastro-intestinai 
tract. By mouth the usual dose is 1 gm. (4 x 
250 mg. tablets) followed by 0.5 to 1 gram every 
three to six hours, but in ventricular tachycardia 
or in a supraventricular tachycardia larger doses 
such as 1.25 grammes at once and 0.75 grammes 
two hourly till normal rhythm intervenes are 
necessary. The total daily dose is usually from 
one to five grammes.
For parenteral administration the safest route 
is probably the intramuscular injection of
I ,  000 mg. Intravenously, 50 mg. can be injected 
every two minutes, with blood pressure readings 
before each injection. If the pressure falls at 
all, the interval between injections should be 
lengthened to 5 or 10 minutes or the drug should 
be stopped. The total intravenous dose should 
not exceed 1,000 mg. The peak effect of an 
intravenous injection occurs in four minutes.21.
Finally, it is worth mentioning briefly the 
subcutaneous injection of 1-2 mg. of Prostig- 
mine or 5 to 20 mg. of mecholvl for the treat­
ment of obstinate paroxysmal tachycardia. 
Intravenous use of 15 mg. of acetylcholine may 
also he of value.33 All these agents require 
caution and the necessity of keeping a syringe 
charged with atropine ready in case of toxic 
effects.
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